Objectives: To estimate survival and evaluate prognostic factors of pediatric patients with central nervous system (CNS) tumors treated in a single center.
Introduction
Central nervous system (CNS) tumors are the second most common cancer among children and the main solid tumor in childhood in the United States. It affects about 21 .3% of all children with malignant diseases, 1 and its annual incidence is 2.5 cases per 100,000. 2 In the whole world, about 8 to 15% of the pediatric tumors are estimated to be in this group, and it is the most frequent pediatric solid tumor. 2, 3 In developing countries, CNS cancers have the third highest incidence rate among children. 3 In the city of Fortaleza, Brazil, age-adjusted incidence from 1998 to 2002 was 1.3 cases per 100,000 children younger than 18 years, which corresponds to an annual incidence of 0.26 cases per 100,000 children. It accounts for 11% of all pediatric cancer diagnoses and is the third most frequent type of childhood cancer, after only leukemia (30%) and lymphoma (15%). 4 
Analysis of survival and prognostic factors of pediatric patients with brain tumor
One third of CNS tumors are diagnosed before 3 years of age. More boys than girls are affected depending on tumor type and patient age. 5 The incidence of this type of tumor has been growing progressively, and survival has improved less than for other cancers. 5 Although CNS tumors are the second most common childhood cancer, they are the most common cause (30%) of death due to cancer in adolescence, and one of the most common causes of death of children after the first year of life, second only to accidents. 5 There was a 1.1% decrease in annual mortality associated with CNS tumors from 1975 to 1995 in the US. 2 Brazilian authors have found no reduction in mortality among children with a diagnosis of brain tumor from 1980 to 1998. 6 In Fortaleza,
Brazil, there was a slight reduction in the number of deaths due to brain tumors among children younger than 15 years from 1.3 in 1980-1982 to 1.1 per 100,000 inhabitants in 1995-1997. 6 Tumors have three main treatment modalities: surgery, radiotherapy and chemotherapy. Surgery (complete resection) is the main treatment for CNS tumors; it is the only treatment necessary for many patients with lowgrade astrocytomas and has the greatest impact on patient survival. Radiotherapy is necessary for patients for whom surgery does not control the disease or for patients that cannot undergo surgery, such as those with medulloblastoma or infiltrative tumors of the pons. Radiotherapy, however,
is not free of short-and long-term side effects, and may especially affect cognition and growth depending on the dose used and the area exposed. Moreover, it is not a routine procedure for children younger than 3 years. 7 Up to the 1990s, the use of chemotherapy for brain tumors was controversial, but a growing number of patients has benefited from this treatment. Currently, chemotherapy is well established for pediatric patients with medulloblastoma and low-grade astrocytomas. 7 Our hospital is a reference center in our state because it is the only one to receive, treat and follow up pediatric patients with brain tumors. As recent studies confirmed the effectiveness of adjuvant radiotherapy and chemotherapy, the progression, prognosis and survival of these patients should be evaluated.
Materials and Methods

Study design
This retrospective cross-sectional study used the 
Population and sample
Patients aged 0 to 18 years were included in the study if they had primary brain tumors diagnosed in 12 Anatomic sites were classified according to ICD-10 and the SEER recommendations. Supratentorial tumors (groups C71.0 to C71.5) were subdivided into diencephalic, midline and other supratentorial (hemispheric or ventricular) to clarify the particular features of these two groups. 13 Surgical resection was classified as complete when the contrast-enhanced area was less than 1 cm according to postoperative imaging.
Analysis and data interpretation
Results were computed and described as absolute values and percentages and summarized as measures of central tendency (median and mean) and dispersion (standard deviation of the mean, 95% confidence interval) and compared with current findings in the literature.
Univariate analysis compared the overall curves obtained using the Kaplan-Meyer product limit estimates and logrank test. Cox regression was used for the multivariate analysis of factors affecting primary outcome. The covariance matrix was examined to determine independence between variables. The proportional hazards test was used to test weighted residuals. 14 The results of multivariate analysis were described as statistical chances of type I error (maximum likelihood estimate) and hazard ratio estimates (HR) using a Wald test. Only the factors that had a statistically significant association with the primary outcome (prognostic factors) are reported.
Calculations and analysis were performed electronically using BrOffice. 
Results
Epidemiological profile
Of the 103 patients included in the study, 90 underwent chemotherapy in our center. There were complete records for 99 patients; 4 were lost to follow up. Four patients in full remission died due to treatment complications or nonassociated causes. Mean age at diagnosis was 7.6 (±3.6), median age was 7.2, and prevalence was greater among boys (1.22:1 male-to-female ratio). A little more than half of the patients came from the metropolitan area (56%).
Tumor histopathological types are summarized in Table   1 . Medulloblastomas and PNET were the most prevalent tumors (38%), followed by low-grade, pilocytic and diffuse astrocytomas (18% altogether), adding up to 56% of the total. The percentage of tumors that were not biopsied was significant (25%), and most affected the brain stem. The cerebellum was the most frequent anatomic site (49%), followed by brain stem tumors (21%). Therefore, 70% of the patients had infratentorial tumors ( Figure 1 ). At the end of the evaluation, 4 patients had been lost to follow-up, 60 had died and 39 were alive. Figure 1B shows findings about histopathological type: medulloblastoma/ PNET (38%), no histological findings (25%), low-grade astrocytoma (18%), ependymoma (12%) and high-grade astrocytoma (7%). Figure 1C shows 
Survival analysis
Overall 5-year survival in the whole cohort was 45%
(37-57) and remained stable and close to this rate along follow-up ( Figure 2 and Table 2 ). Survival was 51% for patients with medulloblastoma and PNET (37-70); 84%
(69-100) for those with low-grade astrocytoma; and 33%
(15-74) for those with ependymomas. We found a lower survival rate for patients with high-grade astrocytomas:
29% at 30 months and 0% at 50 months ( Figure 2 and Table 2 
Prognostic factors for primary outcome only in the subgroup of medulloblastomas and PNET
The only independent prognostic factor in this group was treatment with radiotherapy, which was associated In the analysis of tumor site, no prognostic factor was statistically significant. Despite that, there was an important difference in survival according to site, and patients with diencephalic tumors had a 59% survival at 60 months, whereas patients with brain stem tumors had a survival of only 19% in the same period (Figure 2 ).
Discussion
The main prognostic factors for the primary outcome found for the whole group were histopathological type (high-grade astrocytoma and ependymoma), complete surgical resection and radiotherapy. Age, sex and the other variables did not have any statistically significant effect on survival of the whole cohort. The patients that underwent partial resection or biopsy and the inoperable patients were included in the same group because their survival curves were similar. There was a significant difference between survival curves for patients with completely and incompletely resected tumors, in agreement with other reports in the literature. 16, 17 Tumor site and histopathological type did not have an important correlation with surgical resection, showing that the effect did not depend on patient selection. Radiotherapy also seemed to have an association with better survival in this series. The analysis of subgroups showed that radiotherapy affected the survival of patients with medulloblastomas and PNET or with brain stem tumors, but not those with low-grade astrocytomas. This finding has already been described in the literature, but there are no studies with children only. 18 The indication of radiotherapy in cases of low-grade astrocytoma is usually limited to patients that did not undergo complete resection or had recurrent disease, which limits the evaluation of the role of radiotherapy.
Because of the small number of patients that did not undergo chemotherapy in our series, its impact on survival could not be statistically evaluated. Despite advances in specific pathologies, the role of chemotherapy remains to be better defined. 19 Patients with medulloblastomas or PNET had a better prognosis if they underwent radiotherapy. Those that did not receive radiotherapy were children younger than 3 years, the age group with the worst results and lower survival rates. Postoperative radiotherapy is the main adjuvant treatment for medulloblastoma and PNET. 17 We compared our findings with data published by SEER. 5 Astrocytomas were found at a smaller percentage (65% in SEER versus 25% in our series); medulloblastomas and PNET These limitations should be taken into consideration when interpreting these study results.
